This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Molecule Removal and Ease of Use: A Comparison of Two Different Dialyzers

Sponsored by Baxter Healthcare Corporation

About this trial

Last updated 8 years ago

Study ID

Gambro 1460

Status

Completed

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 16 years ago

What is this trial about?

The Polyflux HD-C4 (Gambro Renal Products) is a new dialyzer based on the existing Polyflux H membrane and dialyzer technology, but which achieves a performance comparable to Polyflux 210H in a significantly smaller device. The objectives of this study are: 1. To compare and contrast small and large molecule removal by the Polyflux HD-C4 and Polyflux 210H dialyzers under conditions of routine hemodialysis; and, 2. To compare and contrast the ease of use of the Polyflux HD-C4 dialyzer with that of the Polyflux 210H under conditions of routine clinical use for hemodialysis.

What are the participation requirements?

Yes

Inclusion Criteria

- Adults 18 years of age or older

- Stable hemodialysis prescription using Polyflux 210H or Polyflux 21R for at least 2 months prior to study enrollment

- Dialyzing through a native fistula or Gore-Tex graft.

- Blood access must be able to provide a blood flow rate of 400 ml/min.

No

Exclusion Criteria

- Non-compliance with dialysis

- Hematocrit less than 28%

- Active Infection

Locations

Location

Status